Franco Benyamin is an associate in the New York office of Latham & Watkins.
As a member of the firm’s Copyright Practice, Franco counsels clients in sophisticated intellectual property disputes involving artificial intelligence, emerging technologies, and creative industries. His practice centers on complex artificial intelligence and copyright litigation matters, and he has experience representing clients in sensitive, high-stakes disputes.
Franco has experience in all stages of copyright and patent litigation at the district court and appellate level, including pre-suit investigation, fact and expert discovery, trials, and post-trial briefing.
Franco maintains an active pro bono practice and earned a Certificate in Public Interest Law during law school. While in law school, Franco was an associate editor for the Washington University Journal of Law and Policy and a student practitioner for the Entrepreneurship & Intellectual Property Clinic.
Prior to his legal career, Franco was a researcher at the University of Chicago, Northwestern University, and Johns Hopkins University. His work investigating genetic variation in immunotherapeutic responses to the treatment of melanoma led to co-authorship of an article in Science Magazine.
Qualifications
Bar Qualification
Delaware
New York
Education
JD, Washington University in St. Louis School of Law, 2020
Latham litigators honored for successful outcomes in New York’s Appellate Division, First Department for Searchlight Capital Partners as well as at the US Internal Trade Commission on behalf of Serendia LLC.
Latham & Watkins teams led by partner Kevin Wheeler recently secured wins in two offensive patent cases tried before the US International Trade Commission for California-based companies Netgear and Serendia.
Latham & Watkins secured a win for Serendia LLC when an administrative law judge ruled that four companies violated the Tariff Act of 1930, finding they infringed on four of Serendia’s patents used for novel radio frequency microneedling medical devices.
Latham honored for representing Avadel in a precedential case against Jazz Pharmaceuticals where the Federal Circuit, in a rare move, ordered Jazz to remove a patent from the FDA’s Orange Book.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.